$SRRK has been mentioned 8 times over the past 12 months by 3 distinct FinTwit voices, with biotech analyst @adamfeuerstein accounting for 6 of those mentions. Discussion began on 2025-08-21 and continued through April 2026. The conversation has centered on Scholar Rock's apitegromab program for spinal muscular atrophy and manufacturing challenges at the Catalent Indiana facility. @adamfeuerstein reported on FDA compliance issues at the manufacturing partner and the company's continued anticipation of resubmission and 2026 U.S. launch following approval, while @penny_ether noted concerns about third-party manufacturing problems in the context of the broader myostatin inhibitor space.